BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 24043737)

  • 1. Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.
    Fung C; Fossa SD; Milano MT; Oldenburg J; Travis LB
    J Clin Oncol; 2013 Oct; 31(30):3807-14. PubMed ID: 24043737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Continuing increased risk of second cancer in long-term testicular cancer survivors after treatment in the cisplatin era.
    Hellesnes R; Kvammen Ø; Myklebust TÅ; Bremnes RM; Karlsdottir Á; Negaard HFS; Tandstad T; Wilsgaard T; Fosså SD; Haugnes HS
    Int J Cancer; 2020 Jul; 147(1):21-32. PubMed ID: 31597192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urological second malignant neoplasms in testicular nonseminoma survivors: a population-based analysis.
    Li H; Zhu C; Wu J; Ma Y; Jin X; Wei X; Wang K; Li H
    Int Urol Nephrol; 2021 Mar; 53(3):471-477. PubMed ID: 33052518
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors.
    Travis LB; Fosså SD; Schonfeld SJ; McMaster ML; Lynch CF; Storm H; Hall P; Holowaty E; Andersen A; Pukkala E; Andersson M; Kaijser M; Gospodarowicz M; Joensuu T; Cohen RJ; Boice JD; Dores GM; Gilbert ES
    J Natl Cancer Inst; 2005 Sep; 97(18):1354-65. PubMed ID: 16174857
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cisplatin-based chemotherapy and the risk of solid tumors in patients with testicular nonseminoma: still a matter of debate.
    Gandaglia G; Karakiewicz PI; Trinh QD; Sun M
    J Clin Oncol; 2014 Apr; 32(11):1167. PubMed ID: 24590641
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiovascular Disease Mortality After Chemotherapy or Surgery for Testicular Nonseminoma: A Population-Based Study.
    Fung C; Fossa SD; Milano MT; Sahasrabudhe DM; Peterson DR; Travis LB
    J Clin Oncol; 2015 Oct; 33(28):3105-15. PubMed ID: 26240226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term risk of cardiovascular disease in 5-year survivors of testicular cancer.
    van den Belt-Dusebout AW; Nuver J; de Wit R; Gietema JA; ten Bokkel Huinink WW; Rodrigus PT; Schimmel EC; Aleman BM; van Leeuwen FE
    J Clin Oncol; 2006 Jan; 24(3):467-75. PubMed ID: 16421423
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Late toxicity after chemotherapy of malignant testicular tumors].
    Jakob A; Kollmannsberger C; Kanz L; Bokemeyer C
    Urologe A; 1998 Nov; 37(6):635-47. PubMed ID: 9887493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries.
    Richiardi L; Scélo G; Boffetta P; Hemminki K; Pukkala E; Olsen JH; Weiderpass E; Tracey E; Brewster DH; McBride ML; Kliewer EV; Tonita JM; Pompe-Kirn V; Kee-Seng C; Jonasson JG; Martos C; Brennan P
    Int J Cancer; 2007 Feb; 120(3):623-31. PubMed ID: 17096341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer.
    van den Belt-Dusebout AW; de Wit R; Gietema JA; Horenblas S; Louwman MW; Ribot JG; Hoekstra HJ; Ouwens GM; Aleman BM; van Leeuwen FE
    J Clin Oncol; 2007 Oct; 25(28):4370-8. PubMed ID: 17906202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metachronous Contralateral Testicular Cancer in the Cisplatin Era: A Population-Based Cohort Study.
    Hellesnes R; Myklebust TÅ; Bremnes RM; Karlsdottir Á; Kvammen Ø; Negaard HFS; Tandstad T; Wilsgaard T; Fosså SD; Haugnes HS
    J Clin Oncol; 2021 Feb; 39(4):308-318. PubMed ID: 33356420
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study.
    Hisada M; Chen BE; Jaffe ES; Travis LB
    J Natl Cancer Inst; 2007 Feb; 99(3):215-22. PubMed ID: 17284716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Solid Cancer After Treatment of Testicular Germ Cell Cancer in the Platinum Era.
    Groot HJ; Lubberts S; de Wit R; Witjes JA; Kerst JM; de Jong IJ; Groenewegen G; van den Eertwegh AJM; Poortmans PM; Klümpen HJ; van den Berg HA; Smilde TJ; Vanneste BGL; Aarts MJ; Incrocci L; van den Bergh ACM; Jóźwiak K; van den Belt-Dusebout AW; Horenblas S; Gietema JA; van Leeuwen FE; Schaapveld M
    J Clin Oncol; 2018 Aug; 36(24):2504-2513. PubMed ID: 29989856
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome of patients with clinical stage I high-risk nonseminomatous germ-cell tumors 15 years after one adjuvant cycle of bleomycin, etoposide, and cisplatin chemotherapy.
    Vidal AD; Thalmann GN; Karamitopoulou-Diamantis E; Fey MF; Studer UE
    Ann Oncol; 2015 Feb; 26(2):374-7. PubMed ID: 25392157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized phase III trial comparing retroperitoneal lymph node dissection with one course of bleomycin and etoposide plus cisplatin chemotherapy in the adjuvant treatment of clinical stage I Nonseminomatous testicular germ cell tumors: AUO trial AH 01/94 by the German Testicular Cancer Study Group.
    Albers P; Siener R; Krege S; Schmelz HU; Dieckmann KP; Heidenreich A; Kwasny P; Pechoel M; Lehmann J; Kliesch S; Köhrmann KU; Fimmers R; Weissbach L; Loy V; Wittekind C; Hartmann M;
    J Clin Oncol; 2008 Jun; 26(18):2966-72. PubMed ID: 18458040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of cisplatin in patients after kidney transplantation with chronic renal insufficiency: Is the benefit higher than potential risks in therapy of non-seminomatous germ cell tumors?
    Pokrivcak T; Lakomy R; Kazda T; Poprach A; Fabian P; Kiss I
    Medicine (Baltimore); 2021 Jun; 100(24):e26381. PubMed ID: 34128899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testicular cancer in 2013: towards personalized medicine--are we there yet?
    Oldenburg J; Fosså SD
    Nat Rev Urol; 2014 Feb; 11(2):68-9. PubMed ID: 24366345
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Solid and Hematologic Neoplasms After Testicular Cancer: A US Population-Based Study of 24 900 Survivors.
    Milano MT; Dinh PC; Yang H; Zaid MA; Fossa SD; Feldman DR; Monahan PO; Travis LB; Fung C
    JNCI Cancer Spectr; 2020 Jun; 4(3):pkaa017. PubMed ID: 32455335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of second benign brain tumors among cancer survivors in the surveillance, epidemiology, and end results program.
    Kutsenko A; Berrington de Gonzalez A; Curtis RE; Rajaraman P
    Cancer Causes Control; 2014 Jun; 25(6):659-68. PubMed ID: 24682745
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Second cancers after testicular cancer diagnosed after 1980 in Sweden.
    Hemminki K; Liu H; Sundquist J
    Ann Oncol; 2010 Jul; 21(7):1546-1551. PubMed ID: 20019089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.